Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer

胰腺癌诊断和治疗策略中心

• 批准号: 10666691
• 负责人: Sanku Mallik
• 金额: $ 189.41万
• 依托单位: NORTH DAKOTA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-03-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10666691
• 关键词: American Cancer Society; Animals; Award; Big Data; Bioinformatics; Biological Models; Biomedical Research; Biometry; Biostatistics Core; COVID-19 pandemic; Centers of Research Excellence; Cessation of life; Clinical; Collaborations; Core Facility; Dedications; Desmoplastic; Diagnosis; Diagnostic; Disease; Drug Delivery Systems; Drug Targeting; Elements; Environment; Epigenetic Process; Equipment; Evaluation; Faculty; Fluorescence; Foundations; Funding; Funding Opportunities; Genetic; Genetic Engineering; Goals; Grant; Histocytochemistry; Histology; Hospitals; Human; Image; Immunohistochemistry; Incidence; Infrastructure; Institution; Journals; Machine Learning; Maintenance; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical center; Mentors; Mission; Modeling; Multiomic Data; Mus; Mutation; Nebraska; Neoplasm Metastasis; North Carolina; North Dakota; Pancreatic Ductal Adenocarcinoma; Paper; Patients; Peer Review; Phase; Pilot Projects; Postdoctoral Fellow; Privatization; Publications; Publishing; R24; Research; Research Infrastructure; Research Personnel; Research Project Grants; Science; Scientist; Secure; Services; Small Business Innovation Research Grant; Social Distance; Survival Rate; Symptoms; Therapeutic; Therapeutic Agents; Time; Tissues; Translational Research; Travel; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Work; biobank; career; design; doctoral student; effective therapy; genetic risk factor; graduate student; imaging modality; improved; member; model development; mortality; mouse model; novel therapeutics; pancreatic cancer model; pancreatic ductal adenocarcinoma model; patient derived xenograft model; professor; recruit; subcutaneous; tenure track; translational study; tumor; American Cancer Society; Animals; Award; Big Data; Bioinformatics; Biological Models; Biomedical Research; Biometry; Biostatistics Core; COVID-19 pandemic; Centers of Research Excellence; Cessation of life; Clinical; Collaborations; Core Facility; Dedications; Desmoplastic; Diagnosis; Diagnostic; Disease; Drug Delivery Systems; Drug Targeting; Elements; Environment; Epigenetic Process; Equipment; Evaluation; Faculty; Fluorescence; Foundations; Funding; Funding Opportunities; Genetic; Genetic Engineering; Goals; Grant; Histocytochemistry; Histology; Hospitals; Human; Image; Immunohistochemistry; Incidence; Infrastructure; Institution; Journals; Machine Learning; Maintenance; Malignant Neoplasms; Malignant neoplasm of pancreas; Medical center; Mentors; Mission; Modeling; Multiomic Data; Mus; Mutation; Nebraska; Neoplasm Metastasis; North Carolina; North Dakota; Pancreatic Ductal Adenocarcinoma; Paper; Patients; Peer Review; Phase; Pilot Projects; Postdoctoral Fellow; Privatization; Publications; Publishing; R24; Research; Research Infrastructure; Research Personnel; Research Project Grants; Science; Scientist; Secure; Services; Small Business Innovation Research Grant; Social Distance; Survival Rate; Symptoms; Therapeutic; Therapeutic Agents; Time; Tissues; Translational Research; Travel; United States National Institutes of Health; Universities; University of Texas M D Anderson Cancer Center; Work; biobank; career; design; doctoral student; effective therapy; genetic risk factor; graduate student; imaging modality; improved; member; model development; mortality; mouse model; novel therapeutics; pancreatic cancer model; pancreatic ductal adenocarcinoma model; patient derived xenograft model; professor; recruit; subcutaneous; tenure track; translational study; tumor

PROJECT SUMMARY Although the survival for other cancers improved during the last ten years, the outlook for pancreatic ductal adenocarcinoma (PDAC) remains grim. The average overall 5-year survival rate for PDAC is 10.8%. The mission of the Center for Diagnostic and Therapeutic Strategies in Pancreatic Cancer (CDTSPC) in Phase II is to enhance and sustain biomedical research infrastructure at North Dakota State University (NDSU) by developing externally-funded, independent translational research of the Junior Investigators, expanding Core Facility services, and recruiting new investigators. The Covid pandemic-related restrictions hampered our progress in Phase I. Still, the investigators received seven nationally competitive research grants totaling $9.6 million, published more than 50 papers, and graduated 17 Ph. D. students. Two Junior Investigators and three pilot project leaders received tenure and promotion. NDSU hired four new Assistant Professors with research emphasis on pancreatic cancer. Two new Core Facilities were set up – Animal Studies and Biostatistics. The two facilities served 19 COBRE and 33 other investigators. The Animal Core Facility created comprehensive mice models for the first time on campus, including 7 patient-derived mouse models (PDX) of pancreatic cancer. CDTSPC is the only established Facility in North Dakota with the capacity to support foundational and translational research on pancreatic cancer. In Phase II, we will further expand the biomedical infrastructure, emphasizing translational research and prepare for a self-sustaining Center through the following Specific Aims. Aim 1. Provide enhanced mentoring to develop sustainable, independent, translational research projects for Junior Investigators. The three investigators will address three urgent challenges in pancreatic cancer: targeted drug delivery to desmoplastic tumors, synthesis and evaluation of new therapeutic agents, and determining epigenetic-genetic alternations in patient tissues for effective treatment. Each Junior Investigator will have two external mentors to encompass foundational and translational aspects. In addition, a clinician-scientist will serve as the Translational Science Liaison for the Center to bridge the foundational and translational elements. Aim 2. Augment biomedical research infrastructure of NDSU by expanding COBRE Core Facilities. We will expand the Animal Studies Core Facility to include tissue histology, imaging modalities, establish and maintain additional genetically engineered models, continue developing the PDX model systems, and establish a tissue biobank of human, PDX, and mouse pancreatic cancer tissues. In addition, the Biostatistics Core Facility will expand services to support projects using "big data," bioinformatics, and machine-learning analysis. Aim 3. Integrate the Center into the national pancreatic cancer network. We will expand collaboration with eminent pancreatic cancer researchers in the US. We will build human capacity by hiring two new tenure track faculty members and recruiting four new Pilot Project investigators with expertise in translational aspects of pancreatic cancer. The Junior Investigators will compete for grants from NIH, NSF, DoD, and private foundations.

项目摘要 尽管过去十年来其他癌症的生存率有所改善，但胰腺导管的前景 腺癌（PDAC）仍然严峻。 PDAC的平均5年生存率为10.8％。这 II期胰腺癌诊断和治疗策略中心（CDTSPC）的任务是 加强和维持北达科他州立大学（NDSU）的生物医学研究基础设施 开发了外部资助，独立翻译的研究人员的研究，扩大了核心 设施服务，并招募新的调查员。共同大流行有关的限制阻碍了我们 第1阶段的进展。 百万，发表了50多篇论文，并毕业了17个博士。两个初级调查员和三名 飞行员项目领导者获得了任期和晋升。 NDSU聘请了四位研究的新助理教授 强调胰腺癌。建立了两个新的核心设施 - 动物研究和生物统计学。这 有两个设施为19家杂货店和其他33位调查人员服务。动物核心设施创造了全面的 小鼠模型首次在校园内，包括胰腺癌的7种患者衍生的小鼠模型（PDX）。 CDTSPC是北达科他州唯一建立的设施，具有支持基础和 胰腺癌的翻译研究。在第二阶段，我们将进一步扩展生物医学基础设施， 强调翻译研究并通过以下特定目标为自我维持的中心做准备。 目标1。提供增强的心理，以开发可持续，独立，翻译的研究项目 初级调查员。这三名调查人员将解决胰腺癌的三个紧急挑战：针对性 药物输送到脱糖性肿瘤，新治疗剂的合成和评估，并确定 患者组织中的表观遗传遗传替代品可进行有效治疗。每个初级调查员将有两个 外部导师涵盖基础和翻译方面。此外，临床科学家将服务 作为中心的转化科学联络，以弥合基础和转化元素。 AIM 2。通过扩大COBRE核心设施来增强NDSU的生物医学研究基础设施。我们将 扩展动物研究核心设施，包括组织组织学，成像方式，建立和维持 其他一般的工程模型，继续开发PDX模型系统并建立组织 人，PDX和小鼠胰腺癌组织的生物库。此外，生物统计学核心设施将 扩展服务以使用“大数据”，生物信息学和机器学习分析来支持项目。 目标3。将中心整合到国家胰腺癌网络中。我们将扩大与 美国著名的胰腺癌研究人员。我们将通过雇用两个新的任期来建立人类能力 教职员工和招募四名新的试点项目调查员，在翻译方面具有专业知识 胰腺癌。初级调查人员将竞争NIH，NSF，DOD和私人基金会的赠款。